Inotropic agents in development

References

• PACKER M: Adaptive and maladaptive actions of angiotensin-II in patients with severe congestive heart failure. Am. J. Kid. Dig. (1987) 10\(Suppl. 1):66–73.
   Google Scholar
• PACKER M: Adverse effects of converting-enzyme inhi-bition in patients with severe congestive heart failure Pathophysiology and management Postgrad. Med. J. (1986) 62\(Supp1.1):179–182.
   Google Scholar
• OM A, HESS ML: Inotropic therapy of the failing myo-cardium. Clin. Cardiol. (1992) 16:5–14.
   Web of Science ®Google Scholar
• Extensive review on inotropic agents.
   Google Scholar
• CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of xsthe Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N. Engl. J. Med. (1987) 916:1429–1435.
   Google Scholar
• Influence of ACE-inhibitors on morbility and mortality
   Google Scholar
• The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection frac-tion and congestive heart failure. N. Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• Influence of enalapril on mortality
   Google Scholar
• COHN JN, JOHNSON G, ZIESCHE 5, COBB F, FRANCIS G, TRISTANI F, SMITH R, DUNKMAN B, LOEB H, WONG M, BHAT G, GOLDMAN S, FLETCHER RD, DOHERTY J, HUGHES V, CARSON P, CINTRON G, SHABETAI R, HAAK-ENSON C: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic conges-tive heart failure. N Engl. J. Med. (1991) 325:303-310. Influence of enalapril on mortality
   Google Scholar
• HARIGAYA S, SCHWARTZ A: Rate of calcium binding anduptake in normal animal and failing human cardiac muscle. Circ. Res. (1969) 25:781–789.
   PubMed Web of Science ®Google Scholar
• LINDEMAYER GE, SORDAHL LA, HARIGAYA S, ALLEN JC,BESCH HR, SCWARTZ A: Some biochemical studies on subcellular system during transportation. Am J. Cardiol (1971) 27:277–283.
   PubMedGoogle Scholar
• GWATHMEYX, COPELAS L, MAC KINNON R, SCHOEN FJ,FELDMAN MD, GROSSMAN W, MORGAN JP: Abnormal Intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. (1987) 61:70–76.
   PubMed Web of Science ®Google Scholar
• ITO Y, SUKO J, CHIDSEY CA: Intracellular calcium and myocardial contractility. V. Calcium uptake of sarco-plasmic reticulum fractions in hypertrophied and fail-ing rabbit hearts. J. Mol. Cell. Cardiol. (1974) 6:237–247.
   Google Scholar
• PACKER M: Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J. Am. Coll. Cardiol. (1988) 12:1299–1317.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ, IVANHOE RJ, DIBIANCO R, ZEIDIS SM, HENDRIX GH, SOMMER Wj, ELKAYAM D, KUKIN ML, MALLIS GI, SOLLANO JA, SHAN-NON J, TANDON PK, DE METES DL: Effect of oral milri-none on mortality in severe chronic heart failure. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• AKERA T, BASKIN SI, TOBIN T, BRODY TM: Ouabain: temporal relationship between inotropic effect and the in vitro binding to, and dissociation from, (Na+,10-ac-tivated ATPase. Naunyn-Schmkylebetg's Arch. Pharmacol. (1973) 277:151–156.
   PubMed Web of Science ®Google Scholar
• COVIT AB, SCHAER GL, SEALEY JE, LARAG JH, CODY RJ: Suppression of the renin-anglotensin system by intra-venous digoxin in chronic congestive heart failure. Am. J. Med. (1983) 75:445–447.
   PubMed Web of Science ®Google Scholar
• FERGUSON DW, BERG Wj, SANDERS JS, ROACH Pj, ICEMPF JS, KIEN7IF ME: Sympathoinhibitory responses to digi-talis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation (1989) 80:65–77.
   PubMed Web of Science ®Google Scholar
• PACKER M: The neurohormonal hypothesis: a theory toexplain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. (1992) 20:248–254.
   PubMed Web of Science ®Google Scholar
• LEE DC-S, JOHNSON RA, BINGHAM JB, LEAHY M, DINSMORE RE, GOROLL All, NEWELL JB, STRAUSS I1W, HABER E: Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl. J. Med. (1982) 306:699–705.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of low doses of digoxin.
   Google Scholar
• GUYATT GH, SULLIVAN MJJ, FALLEN EL, TIHAL H, RIDEOUT E, HALCROW S, NOGRADI S, TOWSEND M, TAYLOR DW: A controlled trial of digoxin in congestive heart failure. Am. J. Cardiol. (1988) 61:371–375.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of low doses of digoxin.
   Google Scholar
• DIBIANCO R, SHABETAI R, KOSTUK W, MORAN j, SCHLANT RC, WRIGHT R: A comparison of oral milri-none, digoxin and their combination in the treatment of patients with mild chronic heart failure. N Engl. J. Med. (1989) 320:677–683.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of low doses of digoxin.
   Google Scholar
• Captopril-Digoxin Multicenter Reserch Group: Comparative effect of therapy with captopril and digoxin in patientswith to moderate heart failure. JAMA (1988) 259:539-544. Safety and efficacy of low doses of digoxin.
   Google Scholar
• PACKER M, GHEORGHIADE M, YOUNG JB, COSTANTINI PJ, ADAMS ICE, CODY RJ, SMITH LK, VAN VOORHEES L,GOURLEY LA, JOLLY MK: Effects of digoxin withdrawal In patients with chronic failure treated with angioten-sin converting-enzyme inhibitors. N. Engl. J. Med. (1993) 329:1–7.
   PubMed Web of Science ®Google Scholar
• Role of the digoxin in menagement of heart failure.
   Google Scholar
• VERROTTA L, ROGERS CB: The poisonous constituents of Etytbropbleum lastantbum. Int. Symposium of thePhytochemical Society of Europ., Losanne, 29 September - 1 October (1993) (Abstract book):71.
   Google Scholar
• Abstract on extraction, isolation and pharmacological charac-terisation of alkaloids of Dythrophleum lasianthum
   Google Scholar
• WATT JM, BREYER-BRANDWIJK MG: In: The Medicinal andPoisonous Plants of Southern and East AfrWa. Livingstone Ltd. Edinburgh and London (1962) p.602–606.
   Google Scholar
• SANDBERG F: Medicinal and toxic plants from equato-rialAfrica: a pharmacological approach. Etnophannacol. (1980) 2:105–108.
   PubMed Web of Science ®Google Scholar
• FRACCAROLLO D, SANTOSTASI G, MARAGNO I, GAIONRM, DORIGO P, CARPENEDO F, FLOREANI M, VEROTTA L: Attiviti cardiotonica di nuovi principi attivi estratti da Etytbropbleumlasiantbum. Abstract send to VII Congress° Nazionale della Società Italiana di Farmacognosia (SIPHAR) Bologna 30 June-2 July 1994.
   Google Scholar
• Mechanism of inotropic action of Dythrophleum lasianthum alka-loids.
   Google Scholar
• KITHAS P, ARTMAN M, THOMPSON WJ, STRADA SJ: Sub-cellular distribution of high affinity type IV cyclic AMP phosphodiesterase activity in rabbit myocardium: rela-tion to the effects of cardiotonic drugs. CircuL Res. (1989) 62:782–789.
   Web of Science ®Google Scholar
• TENOR H, BARTEL S, KRAUSS EG: Cyclic nucleotide phosphodiesterase activity in the rat myocardium: evi-dence of four different PDE subtypes. Blom. Biochem. Acta (1987) 46:749–753.
   Google Scholar
• WEISHAAR RE, CAIN MH, BRISTOL JA: A new generationof phosphodiesterase inhibitors: multiple forms of phosphodiesterase and the potential for drug selectiv-ity. J. Med. Chem. (1985) 28:537–545.
   PubMed Web of Science ®Google Scholar
• PDE as target for inotropic agents.
   Google Scholar
• KATZ AM: Cyclic adenosine monophosphate effects onthe myocardium: a man who blows hot and cold with one breath. J. Am. Coll. Cardiol. (1983) 2:143–149.
   PubMed Web of Science ®Google Scholar
• TRAUTWEIN W, HESCHELER J: Regulation of cardiac Ltype calcium current by phosphorylation and 6-pro-teins. Ann. Rew. Physiol. (1990) 52:257–274.
   PubMed Web of Science ®Google Scholar
• MORGAN JP, PERRAULT CL, MORGAN KG: The cellularbasis of contraction and relaxation in cardiac and vascular smooth muscle. Am. Heart1 (1991) 121:961–968.
   PubMed Web of Science ®Google Scholar
• MORGAN JP: Abnormal intracellular modulation of cal-cium as a major cause of cardiac contractile dysfunc-tion. N. Engl. J. Med. (1991) 325:625–632.
   PubMed Web of Science ®Google Scholar
• SCHMITZ W, VAN DER LEYEN H, MEYER W, NEWMANN J,SCHOLZ H: Phosphodiesterase inhibition and positive effects. J. Card. Pharmacol. (1989) 14\(Suppl. 3):511–514.
   Google Scholar
• KATZ AM: Potential deleterious effect of inotropic agents in the therapy of chronic heart failure. Circula-tion (1986) 73(Suppl.
   Google Scholar
• FARAH AE, ALOUSI AA: New cardiotonic agents search for digitalis substitute. Life Sci. (1978) 22:1139–1148.
   PubMed Web of Science ®Google Scholar
• HONERJAGER P, SCHAFER-KORTING M, REITER M: In-volvement of cyclic AMP in the direct inotropic action of antrinone: biochemical and functional evidence. Naunyn-Schmiedeberg's Arch. Pharmacol. (1981) 318:112–129.
   Google Scholar
• ALOISI AA, JOHNSON DC: Pharmacology of the bipyrid-ine: amrinone and milrinone. Circulation (1986) 73(Suppl. III):III-10-III–24.
   Google Scholar
• VERNON MW, HEEL RC, BROGDEN RN: Enoximone. A review of its pharmacological properties and therapeu-tic potential. Drugs (1991) 42:997–1017.
   Google Scholar
• FISCHER TA, ERBEL R, TREESE N: Current status of phos-phodksterase inhibitors in the treatment of congestive heart failure. Drugs (1992) 44(6):928–945.
   PubMed Web of Science ®Google Scholar
• Extensive review on PDE III inhibitors.
   Google Scholar
• RUEGG JC: Effects of new inotropic agents on calciumsensitivity of contractile proteins. Circulation (1986) 73\(supp1.111):III–78411–84.
   Google Scholar
• Indication of Ca2+-sensitising properties.
   Google Scholar
• BETHKE T, BRUNICHORST D, VAN DER LEYEN H, MEYERW, NIGHUR R, SCHOLZ H: Mechanisms of action and cardiotonic activity of a new phosphodiesterase inhibi-tor, the benzimidazole derivative adibendan (BM 14.478) in guinea-pig hearts. Naunyn-Schmiedeberg's Arch. Pharmacol. (1988) 337:576–582.
   PubMed Web of Science ®Google Scholar
• BRUNKIIORST D, VAN DER LEYEN H, MEYER W, NIGHURR, SCHMIDT-SCHUMAKER C, SCHOLZ H: Relation of posi-tive inotropic and chronotropic effects of pimobendan. UD-CG 212, mikinone and other phosphodiesterase Inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Arch. Pharma-col. (1989) 339:575–583.
   Google Scholar
• FUJINO K, SPERELAKIS N, SOLARO RJ: Sensitization andthe inotropic effect of pimobendan: comparison with miltinone. CircuL Res. (1988) 63:911–922.
   PubMed Web of Science ®Google Scholar
• LEE JA, RUEGG JC, ALLEN DG: Effect of pimobendan, anovel inotropic agent on intracellular calcium and tension in isolated ferret ventricular muscle. Clin. Sci. (1989) 76:609–618.
   PubMed Web of Science ®Google Scholar
• FELDMAN MD, COPEIAS L, GWANTHMEY JK, PHILLIPS P,WARREN SE, SCHOEN FJ, GROSSMAN W, MORGAN JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunc-tion in patients with end-stage heart failure. Circulation (1987) 75:331–339.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM, BAUGHAM KL, LEE WK, GOTTLIEB SH, WEISS JL, BECICER LC, STROBECK JE: Usefulness of OP-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or Idiopathic dilated cardiomyopathy. Am.J. Cardiol. (1991) 68:1203–1210.
   PubMed Web of Science ®Google Scholar
• BARRETT JA, WOLTMANN RE, SWILL° RS, KASIEWSKI C, FAITH WC, CAMBELL HF, PERRONE MH: Pharmacologyof RGW-2938: a cardiotonic agent with vasodilator ac-tivity. j Cardiovasc. Pharmacol. (1990) 16:537–545.
   PubMed Web of Science ®Google Scholar
• First report of cardiac activity of RGW-2938 in vitro.
   Google Scholar
• ARTIGOU JY, SALLOUM J, LE CHAT PH, FOURNIER P, CHARNIOT JC, PAVIE A, BORS U, GANDJBAKHCH I, GROS-GOGEAT Y: Evaluation d'un nouvel agent cardiotonique sur roreilette humaine isolee. Ann. Cardiol. Angiol. (1993) 42(2):79–82.
   PubMedGoogle Scholar
• First report of the activity of RGW-2938 on human heart in vitro.
   Google Scholar
• MOCHIZUKI N, UCHIDA S, MIYATA H: Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonicagents with vasodRatatory properties. J. Cardiovasc. Phartnacol. (1993) 21:983–995.
   PubMedGoogle Scholar
• First report of the cardiac activity of NSP-804 and NSP–805.
   Google Scholar
• BLINKS JR, ENDOH M: Modification of myofibrillar re- sponsiveness to Ca' as an inotropic mechanism Cir-culation (1986) 73(Suppl. III):11185–11198.
   Google Scholar
• Explanation of the mechanism of action of Ca2tsensitisers.
   Google Scholar
• Modulation of cardiac calcium sensitivity: a new ap-proach to increasing the strength of the heart (1993). Lee JA, Allen DC (Eds) Oxford University Press, Oxford. Very recent review on modulation of cardiac Ca2+-sensitivity.
   Google Scholar
• HAGEMEIJER F: Calcium sensitization with pimoben-clan: pharmacology, haemodynamic improvement, andsudden death in patients with chronic congestive heart failure. Eur. Heart J. (1993) 14:551–566.
   PubMed Web of Science ®Google Scholar
• Very recent review of pharmacological properties of pimobendan in failing and non-failing preparations.
   Google Scholar
• LEE JA, ALLEN DG: EMD-53998 sensitizes the contractile proteins to caldum intact ferret ventricular muscle. Circ. Res. (1991) 69:927–936.
   PubMed Web of Science ®Google Scholar
• Calcium-sensitising property of EMD-53998.
   Google Scholar
• KAWABATA Y, ENDOH M: Effects of the positive inot-ropic agent ORG-30029 on developed force and aequorin light transients in intact canine ventricular myocardium. CircuL Res. (1993) 72:597–606.
   PubMed Web of Science ®Google Scholar
• COTTNEY J, LOGAN R, MARSHALL R, NICHOLSON D, SHAHID M, WALKER G: ORG-30029: A new cardiotonic agent possessing both phosphodiesterase inhibitory and calcium-sensitising properties. Cardiovasc. Drug Rev. (1990) 8:179–202.
   Google Scholar
• Calcium-sensitising property of ORG-30029.
   Google Scholar
• LUES I, BEIER N, JONAS R, KLOCKOW M, HAEUSLER G: The two mechanisms of action of the racemic cardio-tonic EMD-53988. Ca sensitisation and phosphodi-esterase inhibition, reside in different enantiomers. J. Cardiovasc. Pbarmacol. (1993) 21:883–892.
   PubMed Web of Science ®Google Scholar
• Pharmacological characterisation of the enantiomers of EMD-53988.
   Google Scholar
• LEE JA, SHAH N, ORCHARD CH: A novel thiadiazinone aderivative fully reverses acidosis-induced depression offorce in cardiac muscle by a calciutn-sensitizing effect. Clin. Sci. (1993) 84:141–144.
   PubMed Web of Science ®Google Scholar
• Cardiac effects of the putative calcium-sensitizing isomers (+)-EMD–57033.
   Google Scholar
• SOLARO RJ, LEE JA, KENTISH JC, ALLEN DG: The effect ofacidosis on ventricular muscle from adult and neonatal rats. Circ. Res. (1988) 634:779–787
   Google Scholar
• ALLEN DG, LFF JA, SMITH GL: The consequences of stimulated ischemia on intracellular Ca2+ and tension in isolated ferret ventricular muscle. j PhysioL (London) (1989) 410:297–323.
   Google Scholar
• BRISTOW MR, GINSBERG R, M1NOBE W, CUBICCIOTTI RS,SAGEMAN WS, LURIE K, BILLINGHAM ME, HARRISON DC, STINSON EB: Decreased catecholamine sensitivity and beta-adrenergk receptor density in failing human hearts. N. Engl. J. Med. (1982) 307:205–211.
   PubMed Web of Science ®Google Scholar
• COLUCCI WS, ALEXANDER RW, WILLIAM GH, RUDE E, HOLMAN BL, KONSTAM MA, WYNNE J, MUDGE GH Jr, BRAUNWALD E: Decreased lymphocyte beta-adrenergic receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol N. Engl. J. Med. (1981) 305:185–190.
   PubMed Web of Science ®Google Scholar
• WEBER KT, ANDREWS V, JANICKI JS, LIKOFF M, REICHEKN: Pirbuterol, an oral beta-adrenergic receptor agonist In the treatment of chronic cardiac failure. Circulation (1982) 66:1262–1267.
   PubMed Web of Science ®Google Scholar
• LAMBERTZ H, MEYER J, ERBEL R: Long-term hemody-namic effects of prenalterol in patients with severe congestive heart failure. Circulation (1984) 69:298–305.
   PubMed Web of Science ®Google Scholar
• ROUBIN GS, CHOONG CY, DEVENISH-MEARES S, SADICK NN, FLETCHER PJ, KELLY DT, HARRIS PJ: P-adrenergic stimulation of the failing ventricule: a double-blind, randomized trial of sustained oral therapy with prenal-terol. Circulation (1984) 69:955–962.
   PubMed Web of Science ®Google Scholar
• NEVE KA, BARNETT DA, MOLINOFF PB: Selective regula-tion of beta-1 and beta-2 adrenerglc receptors by atypi-cal agonists. j Pharmacol. Exp. 7ber. (1985) 235:657–664.
   Google Scholar
• The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet (1990) 336:1–6.
   PubMed Web of Science ®Google Scholar
• Results of large scale placebo-controlled trial.
   Google Scholar
• The German and Austrian Xamoterol Study Group. Double- blind placebo comparison of digoxin and xamoterol in chronic heart failure. Lancet (1988) 1:489–493.
   Google Scholar
• Efficacy of Xamoterol at low doses.
   Google Scholar
• POULER H, Van EYLL T, HANET C, CHERON P, CHATRLIER AA, ROUSSOU ME: Long-term effect of xamoterol on left ventricular diastolic function and late remodelling: a study in patients with anterior myocardial infarction and single-vessel disease. Circulation (1988) 77:1081–1089.
   PubMed Web of Science ®Google Scholar
• ARNOLD JR, MISTRY R, BARNETT DB: Subtype selective regulation of conpling of rat cardiac [3-adrenoceptorsto adenylate cycLise. Eur. j Phartnacol. (1993) 245:285–289.
   PubMed Web of Science ®Google Scholar
• Xamoterol does not downregulate 13-adrenoceptors.
   Google Scholar
• MULIERI LA, HASENFUSS G, LEAVITT B, ALLEN PD, ALPERT NR: Altered myocardial force-frequency relation in hu-man heart failure. Circulation (1992) 85:1743-1750. Alterations in failing heart.
   Google Scholar
• SCHWINGER RHG, BOHM M, ERDMANN E: Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopaty. Am. Heary. (1992) 123:116–128.
   PubMed Web of Science ®Google Scholar
• Alterations in failing heart.
   Google Scholar
• BRODDE OE: Physiology and pharmacology of cardio-vascular catecholamine receptors: Implication for treatment of chronic heart failure. Am. Heart J. (1990) 120:1565–1572.
   PubMed Web of Science ®Google Scholar
• RAJFER SI, ROSSEN JD, DOUGLAS FL, GOLDBERG LI, KARRISON T: Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise ca-pacity in patients with heart failure: Relationship to the generation of N-methyldopamine and to plasma no-repinephrine levels. Circulation (1986) 73:740–748.
   PubMed Web of Science ®Google Scholar
• DEI CAS L, ML'IRA M, NODARI S, RIVA S, MANCA C, VISIOLI0: Lack of tolerance development during chronic ibopamine adminstration to patients with congestive heart failure. Cardiovasc. Drugs 7ber. (1988) 2:221–229.
   Google Scholar
• MARCHIONNI N, CONTI A, DE ALFIERI W, DI BARI M, FERRUCCI L, LOMBARDI A, MOSCHI G, VANNUCCI A: Ibopamine in congestive heart failure refractory to digitalis, diuretics and captopril. J. Clin. Pharmacol. (1986) 26:74–77.
   PubMed Web of Science ®Google Scholar
• DEI CAS L, METRA M, VISIOLI O: Effects of acute chronic ibopamine admtntstration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart fail-ure. Am.]. Cardiol. (1992) 70:629–634.
   PubMed Web of Science ®Google Scholar
• VENTRESCA GP, LODOLA E: CUnicl pharmacokinetics of ibopamine on different disease and conditions. Drugs Res. (1988) 38:1175–1180.
   Web of Science ®Google Scholar
• Metabolism of ibopamine.
   Google Scholar
• ROUSSEAU MF, RAIGOSO J, VAN EYLL C, VAN MECHELEN H, MUSSO S, LOTT' G, POULER H: Effects of intravenous epinine administration on left ventricular systolic per-formance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J. Cardiovasc. Pharmacol. (1992) 19:155–162.
   PubMed Web of Science ®Google Scholar
• Clinical observation with epinine.
   Google Scholar
• ROBERT H, SCHWINGER G, BOHM M, SCHULZ C, SCHMIDT U, SCHMID B, DIENEMANN H, REICHART B, ERDMANN E: Cardiac Inotropic as well as coronary and pulmunary artery actions of epinine in human isolated tissues. J. Pharm. Expt. Ther. (1993) 265:346–357.
   PubMed Web of Science ®Google Scholar
• Inotropic action is not involved in the beneficial effects of epinine in patients with CHF.
   Google Scholar
• PACKER M: The search for the ideal positive Inotropic agent. N. Engl. J. Med. (1993) 329:201–202.
   PubMed Web of Science ®Google Scholar
• SHAFFER JE, GRIZZLE MK, ANDERSON DK, WHELLER TN: The Inotropic and beta blocking effects of a chimeric molecule that putatively inhibits both type M phos-phodiesterase and beta adrenoceptors in anesthetized dogs. J. Pharm. Expt. flier. (1993) 265:1105-1112. Pharmacological characterisation of GI104313.
   Google Scholar
• GALIE N, BRANZI A, MAGNANI G, MELANDRI G, CALDER- ARA I, RAPEZZI C, GRATTONI C, MAGNANI B: Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe con-gestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc. Drugs Ther. (1993) 7:337–347.
   PubMed Web of Science ®Google Scholar
• Usefulness of combined therapy of enoximone and metoprolol.
   Google Scholar
• WONG PC, ALDRICH PE, CHIU AT, EARL RA, HART SD, JOHNSON AL, MA P, McCALL DE, PRICE WA, SMITH RD, WEXLER RR, TLEMMERMANS PBMWM: XB513, a novel calcium agonist with pi adrenergic receptor antagonis-tic property. Pharmacologist (1992) 34:144.
   Google Scholar
• First pharmacological characterisation of XB513.
   Google Scholar
• WONG PC, ALDRICH PE, CHIU AT, EARL RA, HART SD, JOHNSON AL, MA P, MCCALL DE, PRICE WA, SMITH RD, WEXLER RR, T1EMMERMANS PBMWM: Pharmacology of 2-amino-1,4-dihydro-4-(24444-(2-methoxypheny0-1-piperazinylibutylsulfinyllpheny0-6-methyl-5-nitro-3-pyridine carboxylic add methyl ester (X8513), a novel calcium agonist with alpha-1 adrenergic antagonistic property J. Pharm. Expt. Ther. (1993) 265:1088–1095.
   Web of Science ®Google Scholar
• Extensive pharmacolgical characterisation of XB513.
   Google Scholar
• BUGGISCH D, ISENBERG G, RAVENS U, SCHOLTYSIK G: The role of sodium channels in the effects of the cardiotonic compound DP201-106 on contractility and membrane potentials in isolated mammalian heart preparations. Fur.]. Pharmacol. (1985) 118:303–311.
   Web of Science ®Google Scholar
• RAVENS U, WETTWER E, PFEIFER T, HIMMEL H, ARMAH B: Characterization of the effects of the new Inotropic agent BDF 9148 in isolated papillary muscle and myo-cytes of the guinea-pig heart. Br, J. Pharmacol. (1991) 104:1019–1023.
   PubMed Web of Science ®Google Scholar
• Pharmacological characterisation of BDF 9148.
   Google Scholar
• HOEY A, LEHMICUHL A, SANDONY V, RAVENS U: Inot- ropic actions of BDF 9148 and DPI 201-106 and their enantiomers in guinea-pig, rat and human atria. Eur. J. Pharmacol. (1993) 231:477–480.
   PubMed Web of Science ®Google Scholar
• Study of the cardiac activity of enantiomers of DPI 201–106 and of BDF 9148.
   Google Scholar
• SCHOLTYSIK G, SALTZMANN R, BERTHOLD R, HERZIG JW, QUAST U, MARKSTEIN R: DPI 201-106, a novel cardiactive agent, combination of cAMP-Independent positive Inot-ropic, negative chronotropic, action potential prolong-ing and coronary dilatatory properties. Naunyn-Schmiedeberg's Arch. Pharmacol. (1985) 329:316–325.
   Google Scholar
• First description of cardiotonic activity of DPI 201–106.
   Google Scholar
• ROMEY G, QUAST U, PAURON D, FRELIN C, RENAUD JF, LAZDUNSKI M: Na* channels as sites of action of the cardioactive agent DPI 201-106 with agonist and antago-nist enantiomers. Proc. Natl. Acad. Sci. USA (1987) 84:896–900.
   PubMed Web of Science ®Google Scholar
• Study of the cardiotonic activity of DPI 201–106 enantiomers.
   Google Scholar
• NEWMAN WI-I, GROSSMAN SJ, FRANICIS MB, WEBB JG: Increased myocardial adenosine release in heart fail-ure. J. Mol. Cell. Cardiol. (1984) 16:577–580.
   PubMed Web of Science ®Google Scholar
• BELARDINELLI L, WEST A, CRAMPTON R, BERNE RM: Chronotropic and dromotropic actions of adenosine. In: Regulatory function of adenosine (1983). Beme RM, Rail 1W, Rubio R (Eds) NIHOFF, Boston:378–398.
   Google Scholar
• ENDOH M, MARUYAMA M, TAIRA N: Adenosine-induced changes in rate of beating and cyclic nucleotide levels In rat atria: modifications by islet-activating protein. In: Physiology and pharmacology of adenine derivatives (1983). Daly JW, Kuroda Y, Phillis JW, Sclunizu H, Vi M (Eds) Raven Press, New York:127–141.
   Google Scholar
• PELLEG A, MITSOUKA T, MICHELSON EL: Adenosine me-diates the negative chronotropic actions of adenosine 5'-triphosphate in canine sinus node.]. Pharmacol. Exp. Ther. (1987) 242:791–798.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS: The relationship of the swmpathetic nerv-ous system and the renin-anglotensin system in con-gestive heart failure. Am. Heart. J. (1989) 118:642–648.
   PubMedGoogle Scholar
• LUBBE WE, PODZUNIVEIT T, ONE LH: Potential arrhyth-mogenic role of cyclic monophosphate (AMP) and cytosolic caldurn overload: implications for prophylac-tic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J. Am. Coll. Cardiol. (1992) 19:1622–1633.
   PubMed Web of Science ®Google Scholar
• Extensive review of proarrhythmogenic properties of cAMP.
   Google Scholar
• DORIGO P, MARAGNO I: Interaction of amrinone with endogenous adenosine in guinea-pig atria. Br. J. Phar-macol. (1986) 32:623–629.
   Google Scholar
• First demonstration that in guinea-pig atria the cardiac effect of arnrinone is due only to the antagonism towards endogenous adenosine.
   Google Scholar
• EARL CQ, LINDEN J, WEGLICKI WE: Biochemical mecha- nism for the Inotropic effect of the cardiotonic drug milrinone. J. Cardiovasc. Pharmacol. (1986) 8:864-871. First demonstration of the antagonism towards adenosine by milri-none.
   Google Scholar
• PARSON WJ, RAMKUMAR V, STILES GI.: The new cardio-tonic agent sulmazole is an Ai adenosine receptor antagonist and functionally blocks the inhibitory regu-lar Gi. Mol. Pharmacol. (1988) 33:441–448.
   Google Scholar
• DORIGO P, GAION RM, MARAGNO I: Involvement of purine compounds in the inotropk action of milri-none. Cardiovasc. Drugs Ther. (1990) 472:509–514.
   Google Scholar
• First demonstration that in guinea-pig atria the cardiac effect of milrinone is due only to the antagonism towards endogenous adenosine.
   Google Scholar
• UNGERER M, BOHM M, SCHWINGER RHG, ERDMAN E: Antagonism of novel inotropic agents at Al adenosinereceptors and m-cholinoceptors in human myocar-dium. Naunyn-Schmiedeberg's Arch. Pharmacol. (1990) 341:577–585.
   Google Scholar
• Role of endogenous adenosine in the mechanism of action of novel inotropic agent.
   Google Scholar
• DORIGO P, GAION RM, BELLUCO P, BOREA PA, GUERRA L, MOSTI L, FLOREANI M, CARPENEDO F: Antagonism toward endogenous adenosine and inhibition of cGI-PDE in the effects of amrinone, milrinone and related analogues. Gen. Pharmacol. (1992) 23:535–541.
   PubMedGoogle Scholar
• Demonstration that bipyridine molecule may be modified in order to obtain potent inotropic agents acting as adenosine antagonists.
   Google Scholar
• DORIGO P, GAION RM, BELLUCO P, FRACCAROLLO D, MARAGNO I, BOMBIERI G, BENETOLLO F, MOSTI L, ORSINI F: A pharmacological crystallographic, and quantum chemical study of new inotropic agents. J. Med. Chem. (1993) 36:2475–2484.
   PubMed Web of Science ®Google Scholar
• Structure-activity relation of new inotropic agents acting as adeno-sine antagonists.
   Google Scholar
• GINSBURG R, BRISTOW MR, BILLINGHAM ME, STINSON EB, SCHROEDER JS, HARRISON DC: Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am. Heart J. (1983) 106:535–540.
   PubMed Web of Science ®Google Scholar
• DORIGO P: Is inotropic therapy for heart failure an unfufilled promise? Pharmacol. Res. (1992) 26:103–108.
   Google Scholar